Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain

British Journal of Pharmacology

Volumn 151, Issue 6, 2007, Pages 851-859

  Beyermann, M ^a   Heinrich, N ^a   Fechner, K ^a   Furkert, J ^a   Zhang, W ^a   Kraetke, O ^a   Bienert, M ^a   Berger, H ^a  

^a LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

cAMP; CRF receptor; Functional selectivity; G protein coupling; Receptor binding; Signalling domain; Signalling selective ligands

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYCLIC AMP; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; SAUVAGINE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UROCORTIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CELL LINE; CELL MEMBRANE; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; LIGANDS; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447566050     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707293     Document Type: Article

References (21)

1. Berger H, Heinrich N, Wietfeld D, Bienert M, Beyermann M (2006). Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain. Br J Pharmacol 149: 942-947.
2. Beyermann M, Rothemund S, Heinrich N, Fechner K, Furkert J, Dathe M et al. (2000). A role for a helical connector between two receptor binding sites of a long-chain peptide hormone. J Biol Chem 275: 5702-5709.
3. Coy DH, Murphy WA, Sueirasdiaz J, Coy EJ, Lance VA (1985). Structure activity studies on the N-terminal region of growth-hormone releasing-factor. J Med Chem 28: 181-185.
4. Dautzenberg FM, Hauger RL (2002). The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23: 71-77.
5. Davey J (2004). G-protein-coupled receptors: new approaches to maximise the impact of GPCRs in drug discovery - 19-20 January 2004, London, UK. Expert Opin Ther Targets 8: 165-170.
6. Feyen JH, Cardinaux F, Gamse R, Bruns C, Azria M, Trechsel U (1992). N-terminal truncation of salmon-calcitonin leads to calcitonin antagonists - structure activity relationship of n-terminally truncated salmon-calcitonin fragments in vitro and in vivo. Biochem Biophys Res Commun 187: 8-13.
7. Grantcharova E, Furkert J, Reusch HP, Krell H-W, Papsdorf G, Beyermann M et al. (2002). The extracellular N terminus of the endothelin B (ETb) receptor is cleaved by a metalloprotease in an agonist-dependent process. J Biol Chem 277: 43933-43941.
8. Hillhouse EW, Grammatopoulos DK (2006). The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27: 260-286.
9. Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL (1998). -Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 273: 3097-3104.
10. Kenakin T (2003). Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24: 346-354.
11. Kornreich WD, Galyean R, Hernandez JF, Craig AG, Donaldson CJ, Yamamoto G et al. (1992). Alanine series of ovine corticotropin releasing factor-(oCRF) - a structure activity relationship study. J Med Chem 35: 1870-1876.
12. Kristiansen K (2004). Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 103: 21-80.
13. MacKinnon AC, Waters C, Jodrell D, Haslett C, Sethi T (2001). Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor - direct evidence for biased agonism. J Biol Chem 276: 28083-28091.
14. Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M et al. (2005). The oxytocin receptor antagonist atosiban inhibits cell growth via a 'biased agonist' mechanism. J Biol Chem 280: 16311-16318.
15. Rivier J, Rivier C, Vale W (1984). Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science 224: 889-891.
16. Segre GV, Rosenblatt M, Reiner BL, Mahaffey JE, Potts JT (1979). Characterization of parathyroid-hormone receptors in canine renal cortical plasma-membranes using a radioiodinated sulfur-free hormone analog - correlation of binding with adenylate-cyclase activity. J Biol Chem 254: 6980-6986.
17. Takasu H, Gardella TJ, Luck MD, Potts JT, Bringhurst FR (1999). Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: implications for design of signal-specific PTH ligands. Biochemistry 38: 13453-13460.
18. Unson CG, Gurzenda EM, Iwasa K, Merrifield RB (1989). Glucagon antagonists - contribution to binding and activity of the amino-terminal sequence 1-5, position-12, and the putative alpha-helical segment 19-27. J Biol Chem 264: 789-794.
19. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
20. Wess J (1998). Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 80: 231-264.
21. Wietfeld D, Heinrich N, Furkert J, Fechner K, Beyermann M, Bienert M et al. (2004). Regulation of the coupling to different G-proteins of rat corticotropin-releasing factor receptor type 1 in human embryonic kidney 293 cells. J Biol Chem 279: 38386-38394.